Uridine triacetate

SKU: orb2901504

Description

Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS).

Key Properties

• CAS Number: 4105-38-8
• MW: 370.31
• Purity: >98% (HPLC)
• Formula: C₁₅H₁₈N₂O₉
• SMILES: CC(=O)OCC1OC(C(OC(C)=O)C1OC(C)=O)N1C=CC(=O)NC1=O
• Solubility: In Vitro: DMSO : ≥ 100 mg/mL (270.04 mM; )H2O : 10 mg/mL (27.00 mM; Ultrasonic)

Bioactivity

• In Vivo:
  Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced toxicity in 5-FU overdose mice. Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced 5-FU toxicityin DPD deficiency mice. Animal model: 5-FU overdose (i.p. , 300 mg/kg) BALB/c mice model. Dosage: 2 g/kg. Administration: Oral gavage, every 8 h for 15 total doses. Result: Improved the survival rate to 90%, 60%, 30%, 20%, 0% and 0% in the groups initiated within 24, 48, 72, 96, 120 and 144 h, respectively. Animal model: 5-ethynyluracil-induced (i.p. , 2 mg/kg) DPD (dihydropyrimidine dehydrogenase) deficiency mice model. Dosage: 2 g/kg. Administration: Oral gavage, every 8 h for 15 total doses. Result: Improved the survival rate to 100% when initiated 4 h after 5-FU, 80% when initiated within 24 h. Improved the survival rate to 40%, 50%, 20%, 30% and 0% in groups initiated within 48, 72, 96, 120 and 144 h, respectively.
• In Vitro:
  Uridine triacetate inhibits [3H]uridine uptake in ENT1 and ENT2 overexpressed HeLa cells, with IC50s of 28.4 μM and 228.4 μM respectively.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only